DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 18-117/S-032

Aventis Pharmaceuticals
200 Crossing Boulevard
Bridgewater, NJ 08807-0890

Attention: Eric Floyd, Ph.D.
Senior Director, Regulatory Affairs

Dear Dr. Floyd:

Please refer to your supplemental new drug application dated March 4, 2003, received March 7, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Azmacort (triamcinolone acetonide) Inhalation Aerosol.

This "Changes Being Effected" supplemental new drug application provides for the addition of a Post Marketing subsection to the ADVERSE REACTION section of Package insert. In addition, this supplemental new drug application provides for the addition of cataracts and glaucoma to the newly added Post Marketing subsection.

We completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revisions shown in the enclosed labeling. This revision were agreed on in a September 4, 2003 telephone conversation between Sandra Barnes of this Division and Kerry Rothchild of Aventis .

The final printed labeling (FPL) must be identical to the enclosed labeling, including the minor editorial revisions indicated. These revisions are terms of the approval of this application.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-121/S032." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ms. Colette Jackson, Regulatory Project Manager, at (301) 827-5584.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Director
Division of Pulmonary and Allergy Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Badrul Chowdhury
9/4/03 05:39:50 PM